SUMMARY The development of a reticulum cell sarcoma in the lung of a patient with systemic lupus erythematosus treated with azathioprine for 18 months is described. This possible hazard of immunosuppressive therapy is discussed in relation to patients with SLE.
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Tumour induction is recognised as a potential hazard of immunosuppressive therapy, and a high incidence of reticulum cell sarcoma has been observed in renal transplant recipients treated with azathioprine (Hoover and Fraumeni, 1973) . By contrast, only 2 cases of reticulum cell sarcoma developing in patients with systemic lupus erythematosus (SLE) treated with azathioprine have been reported (Goldenberg et al., 1971; Lipsmeyer, 1972) despite the widespread use of this agent over the last decade. We report here a third case and discuss the possible implications of this association. in 1962, when she presented with polyarthralgia, alopecia, Raynaud's phenomenon, and photosensitive rash, and was found to have LE cells. Subsequent DNA-binding values (Farr test) of 90% and 92 % (normal range-below 30%) substantiated the diagnosis of SLE. The patient had been maintained on prednisone in doses ranging from 10 to 60 mg per day from the time of diagnosis, because of severe recurrent vasculitis. Azathioprine was withdrawn 1 month prior to admission to the Hammersmith Hospital because of lack of benefit. Reticulum cell sarcoma in azathioprine-treated systemic lupus erythematosus 95
Discussion
The striking incidence of early lymphoreticular malignancies in renal treatment patients receiving immunosuppressive agents has not been mirrored in other patients receiving these drugs. This therapy might be expected to carry a particular risk of reticuloendothelial system malignancy in SLE with its altered immune status. In the New Zealand B/W F1 hybrid mouse, the close disease model of SLE, the administration of azathioprine resulted in a marked increase in lymphoma frequency (Casey, 1973) . To date only 2 patients with SLE receiving azathioprine developing reticulum cell sarcoma have been reported (Goldenberg, 1971; Lipsmeyer, 1972) .
The author of the first report of a reticulum cell sarcoma developing in a patient with SLE treated with azathioprine urged that the occurrence of any similar cases should be reported and that a registry be maintained for recording malignancies in patients with rheumatic and 'autoimmune' diseases, whether or not they had been given immunosuppressive drugs (Lipsmeyer, 1972 
